Wall Street brokerages expect that Vital Therapies Inc (NASDAQ:VTL) will post earnings per share of ($0.30) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Vital Therapies’ earnings. Vital Therapies reported earnings per share of ($0.37) in the same quarter last year, which suggests a positive year over year growth rate of 18.9%. The business is expected to issue its next quarterly earnings results on Tuesday, March 6th.
On average, analysts expect that Vital Therapies will report full-year earnings of ($1.27) per share for the current year, with EPS estimates ranging from ($1.27) to ($1.26). For the next year, analysts forecast that the company will report earnings of ($1.27) per share, with EPS estimates ranging from ($1.33) to ($1.21). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Vital Therapies.
Vital Therapies (NASDAQ:VTL) last issued its quarterly earnings data on Wednesday, October 25th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.02. During the same quarter in the prior year, the company posted ($0.32) EPS.
Shares of Vital Therapies (NASDAQ VTL) remained flat at $$5.95 during mid-day trading on Thursday. 178,774 shares of the company’s stock traded hands, compared to its average volume of 172,540. Vital Therapies has a 1-year low of $2.25 and a 1-year high of $6.70. The stock has a market cap of $272.24, a P/E ratio of -4.41 and a beta of 5.12.
In related news, Director Muneer A. Satter purchased 150,000 shares of the firm’s stock in a transaction on Monday, December 11th. The shares were acquired at an average price of $4.89 per share, for a total transaction of $733,500.00. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Muneer A. Satter purchased 100,000 shares of the firm’s stock in a transaction on Wednesday, December 13th. The stock was bought at an average price of $5.48 per share, for a total transaction of $548,000.00. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 300,000 shares of company stock worth $1,520,000. 32.60% of the stock is owned by corporate insiders.
A number of hedge funds have recently made changes to their positions in the business. Victory Capital Management Inc. lifted its stake in Vital Therapies by 12.4% in the 4th quarter. Victory Capital Management Inc. now owns 2,925,886 shares of the company’s stock worth $17,409,000 after purchasing an additional 322,797 shares in the last quarter. Bank of Montreal Can purchased a new stake in Vital Therapies in the 4th quarter worth $118,000. Granahan Investment Management Inc. MA lifted its stake in Vital Therapies by 51.4% in the 3rd quarter. Granahan Investment Management Inc. MA now owns 388,282 shares of the company’s stock worth $1,961,000 after purchasing an additional 131,828 shares in the last quarter. Dimensional Fund Advisors LP purchased a new stake in Vital Therapies in the 3rd quarter worth $116,000. Finally, JPMorgan Chase & Co. lifted its stake in Vital Therapies by 1,985.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 25,462 shares of the company’s stock worth $123,000 after purchasing an additional 24,241 shares in the last quarter. Institutional investors and hedge funds own 24.35% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “-$0.30 Earnings Per Share Expected for Vital Therapies Inc (VTL) This Quarter” was published by American Banking News and is owned by of American Banking News. If you are viewing this story on another website, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this story can be read at https://www.americanbankingnews.com/2018/02/01/0-30-earnings-per-share-expected-for-vital-therapies-inc-vtl-this-quarter.html.
Vital Therapies Company Profile
Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vital Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies and related companies with MarketBeat.com's FREE daily email newsletter.